Comparing Expanded Hemodialysis Using Theranova Filter With Other Dialysis Methods in Removing Uremic Toxins in Chronic Kidney Failure

What this Trial Is About

Researchers are investigating different dialysis methods for patients with chronic end-stage renal disease to compare how well they remove small- and medium-sized uremic toxins, control inflammation, and affect erythropoietin resistance. The study focuses on four dialysis techniques expanded hemodialysis HDx using the Theranova 400TM filter, high-flux hemodialysis HF-HD, online hemodiafiltration OL-HDF, and hemodiafiltration with endogenous reinfusion HFR. This observational study aims to personalize dialysis treatment by evaluating these methods over a mid-term period of 12 months. The study analyzes data from about 50 patients divided into four groups based on the dialysis method used, with each group having at least 10 patients treated at a specialized nephrology center from 2018 to 2022. Patients have been receiving their respective dialysis treatments as part of regular clinical care, including tri-weekly sessions lasting at least 210 minutes. No study-specific treatments or visits are added beyond standard clinical practice. Participants clinical data collected during their routine care will be reviewed and analyzed over 18 months after ethics approval. Data include blood parameters and clinical events documented in patients medical records, which will be securely managed and pseudonymized. The study will measure differences in dialysis methods at baseline, 3 months, and 12 months to assess their performance and impact on patients health.

Comparison of Hemodialysis Techniques in the Removal of Uremic Toxins in Chronic Renal Failure